AXSM News and Press, Axsome Therapeutics Inc. From 08/09/22

Commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) fell ~8% in the pre-market even after the company exceeded Street forecasts with its Q2 2022 financials on Tuesday as the investors focus on the regulatory path for the company’s depression candidate AXS-...

Axsome Therapeutics press release ( NASDAQ: AXSM ): Q2 GAAP EPS of -$1.06 beats by $0.18 . Revenue of $8.81M beats by $2.52M . The Company recorded U.S. net sales of Sunosi from the May 9, 2022 acquisition date through the end of the second quarter 20...

Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today ...

Axsome Therapeutics ( NASDAQ: AXSM ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$1.12 (-30.2% Y/Y) and the consensus Revenue Estimate is $6.29M Over the last 3 months, EPS estimates have seen ...

Major earnings expected before the bell on Tuesday include: Bausch Health Companies ( BHC ) Cronos Group ( CRON ) Emerson Electric ( EMR ) Norwegian Cruise Line Holdings ( NCLH ) Workhorse Group ( WKHS ) For further details see: Notable ea...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap growth stocks with 1,000% upside potential is our topic for today. They are usually young companies with a market capitalization (cap) between $300 million and $2 billion. These names are typically more sensitiv...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (Nasd...

Axsome to host conference call and webcast on Tuesday, August 9, 2022 at 8:00 AM Eastern Time NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central ner...

Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More importantly, the firm indicated its upcoming labeling discussion for AXS05 with the ...

There's a reason why the Rocky movies were so successful: Nearly everybody loves a comeback. That isn't just true in entertainment; investors like comeback stories, too. We asked three Motley Fool contributors to pick beaten-down stocks that they think could soar in the second half ...